Login to Your Account



A Platform Hits China

New Tech, New JV: MedImmune Sees Potential Growth for Both

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, September 17, 2012

MedImmune is taking its new YTE technology to China. Last week, the biologics arm of AstraZeneca plc established a joint venture with WuXi AppTec to develop its anti-inflammatory drug MEDI5117 for the China market.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription